GLMD Stock Overview
A biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.75 |
| 52 Week High | US$23.80 |
| 52 Week Low | US$2.73 |
| Beta | 0.80 |
| 11 Month Change | -39.43% |
| 3 Month Change | -23.69% |
| 1 Year Change | -27.68% |
| 33 Year Change | -99.42% |
| 5 Year Change | -99.66% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Shareholder Returns
| GLMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | 2.4% | 2.2% |
| 1Y | -27.7% | 16.2% | 31.7% |
Return vs Industry: GLMD underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: GLMD underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| GLMD volatility | |
|---|---|
| GLMD Average Weekly Movement | 84.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLMD's weekly volatility has increased from 44% to 84% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Allen Baharaff | www.galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GLMD fundamental statistics | |
|---|---|
| Market cap | US$4.22m |
| Earnings (TTM) | -US$6.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs GLMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.32m |
| Earnings | -US$6.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLMD perform over the long term?
See historical performance and comparison